An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next Alberto D’AngeloRobert ChapmanGiandomenico Roviello Review Article Open access 11 August 2022 Pages: 191 - 205
Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics Rajendar K. MittapalliCen GuoDonghua Yin Review Article 14 August 2022 Pages: 207 - 216
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer Justin A. ChenJasmine C. HuynhEdward J. Kim Original Article Open access 30 July 2022 Pages: 217 - 228
Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies Jinhui XueHaipeng HeLi Zhang Original Article 03 August 2022 Pages: 229 - 237
Optimized scaling of translational factors in oncology: from xenografts to RECIST Marcus BaazTim CardilinMats Jirstrand Original Article Open access 03 August 2022 Pages: 239 - 250
A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells Wen ZhangJingwen LiuFujiang Guo Original Article 12 August 2022 Pages: 251 - 265
Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity Janine S. Y. TamElise E. CrameJoanne M. Bowen Original Article Open access 12 August 2022 Pages: 267 - 278
Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia Honami SatoTakahiro KobayashiNaoto Takahashi Short Communication 13 August 2022 Pages: 279 - 284
